1. 24 Phase 1 study in healthy volunteers to assess PK, PD safety & tolerability of BOS161721, an extended half-life anti-IL21 monoclonal antibody. (April 2019) Authors: Valencia, Xavier; Glogowski, Christen; Hussaini, Azra; Mountfield, Richard; Ho, Peter Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and Safety of Anti–Interleukin‐20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. Issue 6 (June 2015) Authors: Šenolt, Ladislav; Leszczynski, Piotr; Dokoupilová, Eva; Göthberg, Marie; Valencia, Xavier; Hansen, Brian Bekker; Cañete, Juan D. Journal: Arthritis & rheumatology Issue: Volume 67:Issue 6(2015) Page Start: 1438 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. (May 2015) Authors: Ganz, Michael L.; Hansen, Brian Bekker; Valencia, Xavier; Strandberg-Larsen, Martin Journal: Journal of medical economics Issue: Volume 18:Number 5(2015) Page Start: 366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗